Biotest Aktiengesellschaft (ETR:BIO3)

Germany flag Germany · Delayed Price · Currency is EUR
28.30
-0.20 (-0.70%)
Mar 10, 2025, 2:53 PM CET
4.81%
Market Cap 1.39B
Revenue (ttm) 707.00M
Net Income (ttm) 68.50M
Shares Out 39.57M
EPS (ttm) 1.73
PE Ratio 16.77
Forward PE n/a
Dividend 0.04 (0.14%)
Ex-Dividend Date n/a
Volume 333
Average Volume 2,247
Open 28.40
Previous Close 28.50
Day's Range 28.30 - 28.40
52-Week Range 22.80 - 29.90
Beta 0.26
RSI 46.63
Earnings Date Mar 28, 2025

About ETR:BIO3

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company’s produ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1946
Employees 2,426
Stock Exchange Deutsche Börse Xetra
Ticker Symbol BIO3
Full Company Profile

Financial Performance

Financial Statements

News

EQS-Adhoc: Biotest AG: CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future.

EQS-Ad-hoc: Biotest AG / Key word(s): Personnel Biotest AG: CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future. 06-March-2025 / 0...

4 days ago - Wallstreet:Online

Biotest AG's Preliminary Results Surpass 2024 Forecasts!

Biotest AG has defied expectations with a remarkable financial performance in 2024, showcasing resilience and strategic prowess. With a revenue surge to €726.2 million and a positive cash flow of €62....

12 days ago - Wallstreet:Online

EQS-Adhoc: Biotest AG publishes preliminary business figures - 2024 forecasts partially exceeded

EQS-Ad-hoc: Biotest AG / Key word(s): Annual Results Biotest AG publishes preliminary business figures - 2024 forecasts partially exceeded 26-Feb-2025 / 18:22 CET/CEST Disclosure of an inside informat...

12 days ago - Wallstreet:Online

Biotest's Big Step: FDA Review for Fibrinogen Biologics

Biotest AG is on the brink of transforming fibrinogen deficiency treatment with its FDA submission, promising safer, faster, and more effective solutions by 2025. Jetzt den vollständigen Artikel lesen

2 months ago - Wallstreet:Online

EQS-News: Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA)

EQS-News: Biotest AG / Key word(s): Regulatory Admission Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA) 09.01.2025...

2 months ago - Wallstreet:Online

EQS-News: Minister of Economic Affairs Mansoori and Lord Mayor Benz visit Biotest's plasma center in Darmstadt and call for plasma donations

EQS-News: Biotest AG / Key word(s): Miscellaneous Minister of Economic Affairs Mansoori and Lord Mayor Benz visit Biotest's plasma center in Darmstadt and call for plasma donations 15.11.2024 / 09:00 ...

4 months ago - Wallstreet:Online

Biotest Boosts Revenue by 4.5% to €523M in First 9 Months!

Biotest has reported a promising financial performance for the first nine months of 2024, with revenues climbing by 4.5% to €523 million. This growth is fueled by strong product sales and strategic de...

4 months ago - Wallstreet:Online

EQS-News: Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million

EQS-News: Biotest AG / Key word(s): 9 Month figures Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million 14.11.2024 / 10:14 CET/CEST The issuer is solely responsible for the co...

4 months ago - Wallstreet:Online

Biotest AG: Revenue & Cash Flow Forecast Cut, EBIT Guidance Steady

Biotest AG has adjusted its 2024 financial outlook, predicting modest revenue growth and revised ROCE and cash flow expectations, while maintaining steady EBIT projections. Jetzt den vollständigen Art...

4 months ago - Wallstreet:Online

EQS-Adhoc: Biotest AG: Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchanged

EQS-Ad-hoc: Biotest AG / Key word(s): Change in Forecast Biotest AG: Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchanged 14-Nov-2024 / 08:56 CET/CEST Disclosure of an i...

4 months ago - Wallstreet:Online

Kedrion and Biotest complete long-term Exclusive Distribution Agreement for Yimmugo® in the US

Contractual terms finalized and definitive agreement between Kedrion and Biotest signed based on framework agreed in July Distribution agreement requires Biotest to supply and Kedrion to purchase mini...

5 months ago - Benzinga

EQS-News: Strategic agreement signed for distribution of Yimmugo in the United States based on the framework established in July

EQS-News: Biotest AG / Key word(s): Market Launch Strategic agreement signed for distribution of Yimmugo in the United States based on the framework established in July 02.10.2024 / 14:00 CET/CEST The...

5 months ago - Wallstreet:Online

EQS-News: Change in the Chief Financial Officer at Biotest AG

EQS-News: Biotest AG / Key word(s): Personnel Change in the Chief Financial Officer at Biotest AG 12.09.2024 / 15:00 CET/CEST The issuer is solely responsible for the content of this announcement. PRE...

6 months ago - Wallstreet:Online

EQS-News: Biotest AG opens 13th plasma collection center in Germany

EQS-News: Biotest AG / Key word(s): Miscellaneous Biotest AG opens 13th plasma collection center in Germany 05.09.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announc...

6 months ago - Wallstreet:Online

EQS-News: Dr. Jörg Schüttrumpf resigns from the Management Board of Biotest AG

EQS-News: Biotest AG / Key word(s): Personnel Dr. Jörg Schüttrumpf resigns from the Management Board of Biotest AG 28.08.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this ...

6 months ago - Wallstreet:Online